Elovl7 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| ELOVL7 | |
|---|---|
| Gene Symbol | ELOVL7 |
| UniProt ID | Q9H8Q0 |
| PDB ID | 5D51, 5D52 |
| Molecular Weight | 33.6 kDa |
| Subcellular Localization | Endoplasmic reticulum membrane |
| Protein Family | ELOVL (Elongation of Very Long Chain Fatty Acids) family |
ELOVL7 (Elongation of Very Long Chain Fatty Acids 7) is an endoplasmic reticulum membrane enzyme that catalyzes the rate-limiting step of very long-chain fatty acid (VLCFA) synthesis[1]. It is encoded by the ELOVL7 gene on chromosome 5p13.3 and plays critical roles in lipid metabolism, membrane biology, and myelin formation.
ELOVL7 catalyzes the first step of very long-chain fatty acid (VLCFA) elongation, converting C14-C16 fatty acids to C18-C26+ fatty acids through a four-step condensation reaction:
ELOVL7 has broad substrate specificity:
VLCFAs synthesized by ELOVL7 are essential for:
ELOVL7 contains several key structural features:
Crystal structures have revealed the catalytic mechanism and substrate access channel[2].
ELOVL7 is expressed in:
ELOVL7 in Alzheimer's disease[3]:
| Agent | Target | Development Status | Indication |
|---|---|---|---|
| ELOVL7 inhibitors | Catalytic site | Preclinical | VLCFA reduction |
| Substrate analogs | Substrate binding | Discovery | Metabolic disorders |
| Gene therapy | ELOVL7 expression | Preclinical | Enzyme deficiency |
The study of Elovl7 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Jakobsson A, et al. Identification and characterization of an enzyme catalyzing the elongation of C20-C22 polyunsaturated fatty acids. Biochem Biophys Res Commun. 2006;350(4):857-862.
[2] Suna S, et al. Structural basis for substrate recognition and product release by ELOVL7. J Lipid Res. 2020;61(10):1385-1396.
[3] International Genomics of Alzheimer's Disease Consortium (IGAP). Convergent genetic and expression mechanisms underlying Alzheimer's disease. Nat Neurosci. 2015;18(9):1345-1358.
[4] Nalls MA, et al. Large-scale meta-analysis of genome-wide association data identifies novel Parkinson's disease risk loci. Lancet Neurol. 2014;13(10):969-979.
[5] Tesseur I, et al. Role of lipids in the pathogenesis of Alzheimer's disease. Acta Neurol Belg. 2022;122(3):641-652.